A booster dose of
The booster was 94% effective at preventing symptomatic Covid infections in the U.S. portion of the Phase III trial, and 75% effective overall when it was given 56 days after the initial dose, the company said in a
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.